Citations

Clear

272 citation(s) found for "Watson, M".

P3698Correlation of lead length with procedural safety outcomes of magnetic resonance imaging in patients with legacy pacemakers and defibrillators
Padmanabhan, Deepak , Naksuk, Niyada , Deshmukh, Abhishek , Mulpuru, Siva K. , Felmlee, Joel P. , Dalzell, Connie, Olson, Nora E., Jondal, Mary Lou, Watson, Robert E. , Cha, Y, Friedman, Paul A. , Kella, Danesh , Isath, Ameesh , Kapa, Suraj , Asirvatham, Samuel J.

Mayo Clinic

European Heart Journal | August 30, 2018 | Volume: 39 | Issue: suppl_1 | Pages: No page available

10.1093/eurheartj/ehy563.p3698 Get It

Abstract 5240: Functional and therapeutic significance of ESR1 gene fusions in breast cancer
Shao, Jieya , Iglesia, Michael D. , Chan, Doug W. , Jin, Cao , Singh, Purba , He, Xiaping , Kosaka, Yoshimasa , Matsunuma, Ryoichi , Crowder, Robert J., Phommaly, Chanpheng, Gonçalves, Rodrigo , Romalho, Susana, Peres, Raquel Mary Rodrigues , Punturi, Nindo , Schmidt, Cheryl, Bartram, Alex, Jou, Eric , Lai, W V., Rogers, Anna , Tobias, Ethan, Parikh, Poojan A., Li, Shunqiang , Cynthia, X. , Thompson, Emily A. , Kavuri, Shyam M. , Creighton, Chad J. , Maher, Christopher A. , Haricharan, Svasti , Lei, Jonathan T. , Zhang, Jin , Anurag, Meenakshi , Hoog, Jeremy , Lai, W V., Hampton, Oliver , Davies, Sherri R. , Suman, Vera J. , Hunt, Kelly K. , Watson, Mark A. , Hoadley, Katherine A. , Thompson, E A., Chen, Xi , Perou, Charles M. , Ellis, Matthew J.

Mayo Clinic

Cancer Research | August 17, 2018 | Volume: 78 | Issue: 13_Supplement | Pages: 5240-5240

10.1158/1538-7445.am2018-5240 Get It

Abstract RNA sequencing detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor positive (ER+) breast cancer but their role in disease pathogenesis remains unclear. Herein we examined multiple in-frame and out-of-frame ESR1 fusions and found only two, both identified in advanced endocrine treatment resistant disease, encoded stable and functional in-frame fusion proteins. In both examples, ESR1-e6>YAP1 and ESR1-e6>PCDH11X, the N-terminal, DNA binding and dimerization motifs encoded by exons 2-6 were fused to C-terminal sequences from the partner gene. Functional properties included estrogen-independent growth, constitutive expression of ER target genes, anti-estrogen resistance, induction of cellular motility in vitro and the development of lung metastasis in vivo. Chromatin immunoprecipitation and RNA sequencing experiments showed both fusions uniquely activated a metastasis-associated transcriptional program. ESR1-e6>YAP1 and ESR1-e6>PCDH11X-induced growth remained sensitive to a CDK4/6 inhibitor, palbociclib, and a patient-derived xenograft (PDX) expressing the ESR1-e6>YAP1 fusion was also responsive. Transcriptionally active ESR1 fusions therefore trigger both endocrine therapy resistance and metastatic progression explaining the association with fatal disease progression, although CDK4/6 inhibitor treatment is predicted to be effective. Citation Format: Jonathan T. Lei, Jieya Shao, Jin Zhang, Michael Iglesia, Doug W. Chan, Jin Cao, Meenakshi Anurag, Purba Singh, Xiaping He, Yoshimasa Kosaka, Ryoichi Matsunuma, Robert Crowder, Jeremy Hoog, Chanpheng Phommaly, Rodrigo Goncalves, Susana Romalho, Raquel M. Peres, Nindo Punturi, Cheryl Schmidt, Alex Bartram, Eric Jou, W V. Lai, Oliver Hampton, Anna Rogers, Ethan Tobias, Poojan Parikh, Sherri R. Davies, Shunqiang Li, Cynthia X. Ma, Vera Suman, Kelly K. Hunt, Mark A. Watson, Katherine A. Hoadley, E A. Thompson, Xi Chen, Shyam M. Kavuri, Chad J. Creighton, Christopher A. Maher, Charles M. Perou, Svasti Haricharan, Matthew J. Ellis. Functional and therapeutic significance of ESR1 gene fusions in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5240.
Laser ablation for mesial temporal epilepsy: a multi-site, single institutional series
Zimmerman, Richard S. , Brinkmann, Benjamin H. , Tatum, William O. , Crepeau, Amy Z. , Woodrum, David A. , Gorny, Krzysztof R. , Felmlee, Joel P. , Watson, Robert E. , Trenerry, Max R., Marsh, W. Richard , Wharen, Robert E. , Hoxworth, Joseph M. , Vibhute, Prasanna , Brinkmann, Benjamin H , Grewal, Sanjeet S. , Worrell, Gregory A. , Gupta, Vivek , Kaufmann, Timothy J. , Gompel, Jamie J. Van

Mayo Clinic

Journal of Neurosurgery | July 6, 2018 | Volume: No volume available | Issue: No issue available | Pages: 1-8

10.3171/2018.2.jns171873 | PMID 29979119 Get It

OBJECTIVE Although it is still early in its application, laser interstitial thermal therapy (LiTT) has increasingly been employed as a surgical option for patients with mesial temporal lobe epilepsy. This study aimed to describe mesial temporal lobe ablation volumes and seizure outcomes following LiTT across the Mayo Clinic’s 3 epilepsy surgery centers. METHODS This was a multi-site, single-institution, retrospective review of seizure outcomes and ablation volumes following LiTT for medically intractable mesial temporal lobe epilepsy between October 2011 and October 2015. Pre-ablation and post-ablation follow-up volumes of the hippocampus were measured using FreeSurfer, and the volume of ablated tissue was also measured on intraoperative MRI using a supervised spline-based edge detection algorithm. To determine seizure outcomes, results were compared between those patients who were seizure free and those who continued to experience seizures. RESULTS There were 23 patients who underwent mesial temporal LiTT within the study period. Fifteen patients (65%) had left-sided procedures. The median follow-up was 34 months (range 12–70 months). The mean ablation volume was 6888 mm 3 . Median hippocampal ablation was 65%, with a median amygdala ablation of 43%. At last follow-up, 11 (48%) of these patients were seizure free. There was no correlation between ablation volume and seizure freedom (p = 0.69). There was also no correlation between percent ablation of the amygdala (p = 0.28) or hippocampus (p = 0.82) and seizure outcomes. Twelve patients underwent formal testing with computational visual fields. Visual field changes were seen in 67% of patients who underwent testing. Comparing the 5 patients with clinically noticeable visual field deficits to the rest of the cohort showed no significant difference in ablation volume between those patients with visual field deficits and those without (p = 0.94). There were 11 patients with follow-up neuropsychological testing. Within this group, verbal learning retention was 76% in the patients with left-sided procedures and 89% in those with right-sided procedures. CONCLUSIONS In this study, there was no significant correlation between the ablation volume after LiTT and seizure outcomes. Visual field deficits were common in formally tested patients, much as in patients treated with open temporal lobectomy. Further studies are required to determine the role of amygdalohippocampal ablation.
Gene Therapy for Osteoarthritis: Pharmacokinetics of Intra-Articular Self-Complementary Adeno-Associated Virus Interleukin-1 Receptor Antagonist Delivery in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 90-100

10.1089/humc.2017.142 | PMID 29869540 Get It

Self-Complementary Adeno-Associated Virus–Mediated Interleukin-1 Receptor Antagonist Gene Delivery for the Treatment of Osteoarthritis: Test of Efficacy in an Equine Model
Levings, Rachael S. Watson, Broome, Ted A., Rice, Brett L., Gibbs, Eric P., Myara, David A., Hyddmark, E. Viktoria, Zarezadeh, Ali , Levings, Padraic P., Lu, Yuan , White, Margaret , Dacanay, E. Anthony, Foremny, Gregory B., Evans, Christopher H. , Morton, Alison J. , Winter, Mathew, Dark, Michael J. , Nickerson, David M., Colahan, Patrick T., Ghivizzani, Steven C. , Smith, Andrew D. , Nasri, Elham , Foremny, Gregory B.

Mayo Clinic

Human Gene Therapy Clinical Development | June 5, 2018 | Volume: 29 | Issue: 2 | Pages: 101-112

10.1089/humc.2017.143 | PMID 29869535 Get It

0867 Sleep Duration and Hypertension among >700,000 Adults by Age and Sex: A Report of the National Healthy Sleep Awareness Project
Grandner, Michael A. , Mullington, Janet , Hashmi, Sarah D., Redeker, Nancy S. , Watson, Nathaniel F. , Morgenthaler, Timothy I.

Mayo Clinic

Sleep | April 27, 2018 | Volume: 41 | Issue: suppl_1 | Pages: A322-A322

10.1093/sleep/zsy061.866 Get It

Occipital neuralgia associates with high cervical spinal cord lesions in idiopathic inflammatory demyelinating disease
Kissoon, Narayan , Watson, James C. , Kantarci, Orhun H. , Kissoon, Narayan R , Boes, Christopher J.

Mayo Clinic

Cephalalgia | April 9, 2018 | Volume: 39 | Issue: 1 | Pages: 21-28

10.1177/0333102418769953 | PMID 29629601 Get It

Background The association of trigeminal neuralgia with pontine lesions has been well documented in multiple sclerosis, and we tested the hypothesis that occipital neuralgia in multiple sclerosis is associated with high cervical spinal cord lesions. Methods We retrospectively reviewed the records of 29 patients diagnosed with both occipital neuralgia and demyelinating disease by a neurologist from January 2001 to December 2014. We collected data on demographics, clinical findings, presence of C2-3 demyelinating lesions, and treatment responses. Results The patients with both occipital neuralgia and multiple sclerosis were typically female (76%) and had a later onset (age > 40) of occipital neuralgia (72%). Eighteen patients (64%) had the presence of C2-3 lesions and the majority had unilateral symptoms (83%) or episodic pain (78%). All patients with documented sensory loss (3/3) had C2-3 lesions. Most patients with progressive multiple sclerosis (6/8) had C2-3 lesions. Of the eight patients with C2-3 lesions and imaging at onset of occipital neuralgia, five (62.5%) had evidence of active demyelination. None of the patients with progressive multiple sclerosis (3/3) responded to occipital nerve blocks or high dose intravenous steroids, whereas all of the other phenotypes with long term follow-up (eight patients) had good responses. Conclusions A cervical spine MRI should be considered in all patients presenting with occipital neuralgia. In patients with multiple sclerosis, clinical features in occipital neuralgia that were predictive of the presence of a C2-3 lesion were unilateral episodic symptoms, sensory loss, later onset of occipital neuralgia, and progressive multiple sclerosis phenotype. Clinical phenotype predicted response to treatment.
207Clinical utility of performing magnetic resonance imaging in patients with cardiac implantable electronic devices in situ
Padmanabhan, Deepak , Tandon, Navdeep, Mulpuru, Siva K. , Mehta, Ramila A. , Dalzell, Connie, Olson, Nora E., Felmlee, Joel P. , Jondal, Mary Lou, Watson, Robert E. , Cha, YONG-M, Friedman, Paul A. , Kella, Danesh , Deshmukh, Amrish , Kapa, Suraj , Asirvatham, Samuel J.

Mayo Clinic

EP Europace | March 19, 2018 | Volume: 20 | Issue: suppl_1 | Pages: i22-i23

10.1093/europace/euy015.056 Get It